Skip to content

Neratinib

Generic Medicine With 2 Brands Available In Bangladesh. Read What It Is For And How It Is Taken, Then Compare The Brands By Strength, Maker And Price.

Generic Guide

About Neratinib

What This Generic Is For, How It Is Taken, And What To Watch For.

Indications

Breast cancer Extended Adjuvant Treatment of Early-Stage Breast Cancer: Neratinib as a single agent is indicated for the extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (HER 2 )- positive breast cancer, to follow adjuvant Trastuzumab-based therapy ... Read more Extended Adjuvant Treatment of Early-Stage Breast Cancer: Neratinib as a single agent is indicated for the extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (HER 2 )- positive breast cancer, to follow adjuvant Trastuzumab-based therapy. Advanced or Metastatic Breast Cancer: Neratinib in combination with Capecitabine is indicated for the treatment of adult patients with advanced or metastatic HER 2 -positive breast cancer who have received two or more prior anti-HER 2 based regimens in the metastatic setting.

Dosage And Administration

Antidiarrheal Prophylaxis: Antidiarrheal prophylaxis is recommended during the first 2 cycles (56 days) of treatment and should be initiated with the first dose of Neratinib. Additional antidiarrheal agents may be required to manage diarrhea in patients with loperamide-refractory diarrhea. Neratinib dose interruptions and dose reductions may also be required to manage diarrhea. The recommended dose of Neratinib is 240 mg (six tablets) given orally once daily with food, continuously for one year. Patients should be instructed to take Neratinib at approximately the same time every day. Neratinib tablets should be swallowed whole (tablets should not be chewed, crushed, or split prior to swallowing). If a patient misses a dose, missed dose should not be replaced, and patients should be instructed to resume Neratinib with the next scheduled daily dose. Or, as directed by the registered physicians. Dose Modifications: For Adverse Reactions: Neratinib dose modification is recommended based on individual safety and tolerability. Neratinib should be discontinued for patients who fail to recover to Grade 0-1 from treatment-related toxicity, for toxicities that result in a treatment delay >3 weeks, or for patients that are unable to tolerate 120 mg daily. Additional clinical situations may result in dose adjustments as clinically indicated (e.g. intolerable toxicities, persistent Grade 2 adverse reactions, etc.). Recommended starting dose: 240 mg daily First dose reduction: 200 mg daily Second dose reduction: 160 mg daily Third dose reduction: 120 mg daily

Side Effects

Diarrhea, Hepatotoxicity.

Precautions And Warnings

Diarrhea: Aggressively manage diarrhea occurring despite recommended prophylaxis with additional antidiarrheals, fluids, and electrolytes as clinically indicated. Withhold Meratinib in patients experiencing severe and/or persistent diarrhea. Permanently discontinue Meratinib in patients experiencing Grade 4 diarrhea or Grade ≥ 2 diarrhea that occurs after maximal dose reduction. Hepatotoxicity: Monitor liver function tests monthly for the first 3 months of treatment, then every 3 months while on treatment and as clinically indicated. Withhold Meratinib in patients experiencing Grade 3 liver abnormalities and permanently discontinue Meratinib in patients experiencing Grade 4 liver abnormalities. Embryo-Fetal Toxicity: Meratinib can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception.

Pregnancy And Lactation

Neratinib can cause fetal harm when administered to a pregnant woman. There are no available data in pregnant women to inform the drug-associated risk. Pregnant women should be advised of the potential risk to a fetus. No data are available regarding the presence of Neratinib or its metabolites in human milk or its effects on the breastfed infant or on milk production. Because of the potential for serious adverse reactions in breastfed infants from Neratinib, lactating women should be advised not to breastfeed while taking Neratinib and for at least 1 month after the last dose. Neratinib can cause fetal harm when administered to a pregnant woman. Females of reproductive potential should have a pregnancy test prior to starting treatment with Neratinib. Females: Females of reproductive potential should be advised to use effective contraception during treatment with Neratinib and for at least 1 month after the last dose. Males: Male patients with female partners of reproductive potential should be advised to use effective contraception during treatment and for 3 months after the last dose of Neratinib.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Clinical Details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Available Brand Names: 2

Sorted By
Tablet

Hernix 40 mg

Generic: Neratinib

56.99Taka / Unit

View Medicine
Tablet

Hertinib 40 mg

Generic: Neratinib

Price Not Available

View Medicine

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250